Q1 2026 Quest Diagnostics Inc Earnings Call Transcript
Key Points
- Quest Diagnostics Inc (DGX) reported a strong first quarter with a revenue growth of over 9%, primarily driven by organic revenue growth.
- The company increased its adjusted diluted earnings per share by approximately 13%, supported by productivity gains from automation and AI.
- Quest Diagnostics Inc (DGX) raised its revenue and EPS guidance for the year, reflecting confidence in continued strategic focus and momentum.
- The company experienced double-digit revenue growth in several key clinical areas, including brain health and cardiometabolic testing.
- Quest Diagnostics Inc (DGX) is advancing its joint venture with Corewell Health, with plans to open a state-of-the-art lab in Southeast Michigan next year.
- The business mix from collaborations with Fresenius Medical Care and Corewell Health impacted total revenue per requisition, which was down 1.3% compared to the prior year.
- Cash from operations was lower than the previous year due to the timing of operating receipts and disbursements and higher bonus payments.
- The company expects some negative weather impacts in the second half of the year, which could affect revenue and EPS.
- Project Nova expenses are expected to be more significant in the second half of the year, potentially impacting margins.
- Higher fuel costs are anticipated to impact the company's expenses, with an estimated $7 million to $10 million increase embedded in guidance.
Welcome to the Quest Diagnostics first quarter 2026 conference call. At the request of the company, this call is being recorded. The entire contents of this call, including the presentation and question-and-answer session that will follow are the copyrighted property of Quest Diagnostics with all rights reserved.
Any redistribution, retransmission or rebroadcast of this call in any form without written consent of Quest Diagnostics is strictly prohibited. Now I'd like to turn the conference over to Dan Haemmerle, Interim Vice President of Investor Relations for Quest Diagnostics. Please go ahead.
Thank you, and good morning. I'm joined by Jim Davis, our Chairman, Chief Executive Officer and President; and Sam Samad, our Chief Financial Officer. During this call, we may make forward-looking statements and will discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the tables to our earnings press release. Actual results may differ materially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
